Smart Money APP news, Zhejiang Dayang Biotech Group (003017.SZ) released its interim report for the first half of 2024. During the reporting period, the company achieved revenue of 0.437 billion yuan, a year-on-year decrease of 9.23%. The net income attributable to shareholders of the listed company was 31.4363 million yuan, an increase of 31.77% compared to the same period last year. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 29.0902 million yuan, an increase of 47.43% compared to the same period last year. The basic earnings per share were 0.3857 yuan.